Sidley has advised Opus Genetics on the deal. Opus Genetics, Inc., a clinical-stage gene therapy company focused on inherited retinal diseases, has entered into a strategic...
Opus Genetics Secures $155 Million Structured Financing from Oberland Capital
Ocuphire Pharma’s Acquisition of Opus Genetics
Sidley Austin represented Ocuphire Pharma, Inc. in the transaction, and Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan represented Opus Genetics Inc. Wilson Sonsini Goodrich & Rosati...